Vanguard Group Inc. decreased its holdings in shares of Lucira Health, Inc. (NASDAQ:LHDX) by 32.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 427,954 shares of the company’s stock after selling 206,948 shares during the quarter. Vanguard Group Inc. owned about 1.11% of Lucira Health worth $2,841,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of LHDX. UBS Group AG bought a new stake in Lucira Health during the 1st quarter valued at $37,000. Morgan Stanley bought a new stake in Lucira Health during the 1st quarter valued at $62,000. Cypress Point Wealth Management LLC raised its holdings in Lucira Health by 19.7% during the 2nd quarter. Cypress Point Wealth Management LLC now owns 12,177 shares of the company’s stock valued at $81,000 after acquiring an additional 2,000 shares during the period. California State Teachers Retirement System bought a new stake in Lucira Health during the 1st quarter valued at $191,000. Finally, Citadel Advisors LLC bought a new stake in Lucira Health during the 1st quarter valued at $195,000. 42.02% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently commented on LHDX shares. Lifesci Capital lowered shares of Lucira Health from an “outperform” rating to a “market perform” rating in a research report on Friday, August 13th. Zacks Investment Research upgraded shares of Lucira Health from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a research report on Wednesday.
Lucira Health (NASDAQ:LHDX) last announced its earnings results on Thursday, November 11th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.04. Lucira Health had a negative net margin of 230.43% and a negative return on equity of 43.84%. Sell-side analysts forecast that Lucira Health, Inc. will post -1.77 EPS for the current fiscal year.
Lucira Health Company Profile
Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.
Read More: Death Cross
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.